ProQR Therapeutics News

ProQR Therapeutics Analyst Ratings

BenzingaApr 18 23:57

ProQR Therapeutics Analyst Ratings

BenzingaMar 14 18:26

Raymond James Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $4

BenzingaNov 8, 2023 19:18

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

BenzingaNov 8, 2023 18:19

ProQR Therapeutics Analyst Ratings

BenzingaNov 8, 2023 18:17

Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position

TipRanksNov 8, 2023 03:35

Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8

BenzingaSep 18, 2023 21:41

ProQR Therapeutics Analyst Ratings

BenzingaSep 18, 2023 21:39

ProQR Therapeutics Analyst Ratings

BenzingaAug 7, 2023 18:14

ProQR Therapeutics Analyst Ratings

BenzingaAug 4, 2023 16:59

Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating

MT NewswiresMay 24, 2023 18:32

Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating

MT NewswiresMay 17, 2023 22:10

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

BenzingaMay 17, 2023 18:26

HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating

MT NewswiresMar 30, 2023 21:33

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $6 Price Target

BenzingaMar 30, 2023 21:15

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $5

BenzingaMar 30, 2023 18:25

Tesla To $175? Here Are 10 Other Price Target Changes For Friday

Benzinga Real-time NewsDec 23, 2022 22:26

Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating

MT NewswiresDec 23, 2022 20:42

Cantor Fitzgerald Upgrades ProQR Therapeutics to Overweight From Neutral, Adjusts Price Target to $5 From $0.80

MT NewswiresDec 23, 2022 00:17